Iron overload due to red blood cell (RBC) transfusions is associated with morbidity and mortality in lower-risk myelodysplastic syndrome (MDS) patients. Many studies have suggested improved survival after iron chelation therapy (ICT), but valid data are limited. The aim of this study was to assess the effect of ICT on overall survival and hematologic improvement in lower-risk MDS patients in the European MDS registry. We compared chelated patients with a contemporary, non-chelated control group within the European MDS registry, that met the eligibility criteria for starting iron chelation. A Cox proportional hazards model was used to assess overall survival (OS), treating receipt of chelation as a time-varying variable. Additionally, chelated and non-chelated patients were compared using a propensity-score matched model. Of 2,200 patients, 224 received iron chelation. The hazard ratio and 95% confidence interval for OS for chelated patients, adjusted for age, sex, comorbidity, performance status, cumulative RBC transfusions, Revised-International Prognostic Scoring System (IPSS-R), and presence of ringed sideroblasts was 0.50 (0.34-0.74). The propensity-score analysis, matched for age, sex, country, RBC transfusion intensity, ferritin level, comorbidity, performance status, and IPSS-R, and, in addition, corrected for cumulative RBC transfusions and presence of ringed sideroblasts, demonstrated a significantly improved OS for chelated patients with a hazard ratio of 0.42 (0.27-0.63) compared to non-chelated patients. Up to 39% of chelated patients reached an erythroid response. In conclusion, our results suggest that iron chelation may improve OS and hematopoiesis in transfused lower-risk MDS patients. This trial was registered at clinicaltrials.gov identifier: 00600860.

Center of Hematology and Bone Marrow Transplantation Fundeni Clinical Institute Bucharest Romania

Centre for Clinical Transfusion Research Sanquin Research Leiden the Netherlands

Clinic of Hematology Clinical Center of Vojvodina Faculty of Medicine University of Novi Sad Novi Sad Serbia

Department of Clinical Epidemiology Leiden University Medical Center Leiden the Netherlands

Department of Clinical Hematology Institute of Hematology and Blood Transfusion Praha Czech Republic

Department of Haematology Aarhus University Hospital Aarhus Denmark

Department of Haematology Aberdeen Royal Infirmary Aberdeen UK

Department of Haematology Hospital Universitario y Politécnico La Fe Valencia Spain

Department of Haematology Oncology and Clinical Immunology Universitätsklinik Düsseldorf Düsseldorf Germany

Department of Haematology Oncology and Internal Medicine Warszawa Medical University Warszawa Poland

Department of Hematology Cancer Center Amsterdam VU University Medical Center Amsterdam the Netherlands

Department of Hematology Hospital da Luz Lisbon Portugal

Department of Hematology Oncology Fondazione Istituto Di Ricovero e Cura a Carettere Scientifico Policlinico San Matteo University of Pavia Pavia Italy

Department of Hematology Radboud University Medical Center Nijmegen the Netherlands

Department of Internal Medicine 5 Innsbruck Medical University Innsbruck Austria

Department of Internal Medicine Division of Hematology Merkur University Hospital Zagreb Croatia

Department of Medicine A Tel Aviv Sourasky Medical Center and Sackler Medical Faculty Tel Aviv University Tel Aviv Israel

Department of Medicine Division of Hematology Karolinska Institutet Stockholm Sweden

Department of Medicine Division of Hematology University of Patras Medical School Patras Greece

Department of Tumor Immunology Nijmegen Center for Molecular Life Sciences Radboud University Medical Center Nijmegen the Netherlands

Epidemiology and Cancer Statistics Group Department of Health Sciences University of York York USA

Service d'Hématologie Centre Hospitalier Universitaire Brabois Vandoeuvre Nancy France

Service d'Hématologie Hôpital Saint Louis Assistance Publique des Hôpitaux de Paris and Université Paris 7 Paris France

St James's Institute of Oncology Leeds Teaching Hospitals Leeds UK

Unit Transfusion Medicine Sanquin Blood Bank Amsterdam the Netherlands

Zobrazit více v PubMed

Nimer SD. Myelodysplastic syndromes. Blood.2008;111(10):4841–4851. PubMed

Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program.2013;2013:447–456. PubMed

Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997; 89(3):739–761. PubMed

Powell LW, Seckington RC, Deugnier Y. Haemochromatosis. Lancet. 2016; 388(10045):706–716. PubMed

Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079–2088. PubMed

Porter JB, de Witte T, Cappellini MD, et al. New insights into transfusion-related iron toxicity: Implications for the oncologist. Crit Rev Oncol Hematol. 2016;99:261–271. PubMed

Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res. 2010; 34(7):864–870. PubMed

Raptis A, Duh MS, Wang ST, et al. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion. 2010; 50(1):190–199. PubMed

Neukirchen J, Fox F, Kündgen A, et al. Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry. Leuk Res. 2012; 36(8):1067–1070. PubMed

Delforge M, Selleslag D, Beguin Y, et al. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014; 38(5):557–563. PubMed

Messa E, Biale L, Castiglione A, et al. Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. Leuk Lymphoma. 2017; 58(11):2752–2754. PubMed

Angelucci E, Santini V, Di Tucci AA, et al. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014; 92(6):527–536. PubMed

Nolte F, Höchsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013; 92(2):191–198. PubMed

Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol. 1996; 94(2):288–299. PubMed

List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol. 2012; 30(17):2134–2139. PubMed

Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012; 9(9):1364–1371. PubMed PMC

Breccia M, Voso MT, Aloe Spiriti MA, et al. An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. Ann Hematol. 2015; 94(5):771–777. PubMed

Bennett JM. World Health Organization; classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol. 2000; 72(2):131–133. PubMed

Caliendo M, Kopeinig S. SOME PRACTICAL GUIDANCE FOR THE IMPLEMENTATION OF PROPENSITY SCORE MATCHING. Journal of Economic Surveys. 2008; 22(1):31–72.

Rosenbaum PR, Rubin DB. Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity Score. The American Statistician. 1985; 39(1):33–38.

Stürmer T, Joshi M, Glynn RJ, et al. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006; 59(5):437–447. PubMed PMC

Schafer JL. Analysis of Incomplete Multivariate Data: Taylor & Francis, 1997.

Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res. 2002;11(2):68–74. PubMed PMC

Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419–425. PubMed

Zeidan AM, Hendrick F, Friedmann E, et al. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. J Comp Eff Res. 2015; 4(4):327–340. PubMed PMC

Mainous AG, Tanner RJ, Hulihan MM, et al. The impact of chelation therapy on survival in transfusional iron overload: a meta-analysis of myelodysplastic syndrome. Br J Haematol. 2014; 167(5):720–723. PubMed PMC

Remacha Á, Arrizabalaga B, Villegas A, et al. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015; 94(5):779–787. PubMed

Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years. Leuk Res. 2017;56:88–95. PubMed

Angelucci E, Li J, Greenberg PL, et al. Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-over-loaded patients with low- and intermediate-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double blind Telesto study. Blood, annual meeting abstracts 2018;132(S1):abstract 234.

Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017; 179(1):83–97. PubMed

de Swart L, Reiniers C, Bagguley T, et al. Labile plasma iron levels predict survival in patients with lower-risk Myelodysplastic syndromes. Haematologica. 2018; 103(1):69–79. PubMed PMC

Hoeks M, Bagguley T, Roelofs R, et al. Elevated labile plasma iron (LPI) levels in patients with lower-risk myelodysplastic syndromes (MDS) are associated with decreased quality of life and reduced overall survival. Blood, annual meeting abstracts 2018;132(S1):abstract 4392.

Wermke M, Eckholdt J, Götze KS, et al. Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trial. Lancet Haematol. 2018; 5:e201–210. PubMed

Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191–201. PubMed

Pilo F, Angelucci E. A storm in the niche: Iron, oxidative stress and haemopoiesis. Blood Rev. 2018; 32(1):29–35. PubMed

Taher AT, Saliba AN, Kuo KH, et al. Safety and Pharmacokinetics of the Oral Iron Chelator SP-420 in β-thalassemia. Am J Hematol. 2017; 92(12):1356–1361. PubMed

Hartmann J, Braulke F, Sinziq U, et al. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes. Leuk Res. 2013; 37(3):327–332. PubMed

Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008:166–175. PubMed

Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594–7603. PubMed

Greenberg PL, Attar E, Bennett JM, et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw. 2011; 9(1):30–56. PubMed PMC

Pimková K, Chrastinová L, Suttnar J, et al. Plasma levels of aminothiols, nitrite, nitrate, and malondialdehyde in myelodysplastic syndromes in the context of clinical outcomes and as a consequence of iron overload. Oxid Med Cell Longev. 2014. January; DOI 10.1155/2014/416028. PubMed DOI PMC

de Souza GF, Barbosa MC, Santos TE, et al. Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. J Clin Pathol. 2013; 66(11):996–998. PubMed

Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study